(NASDAQ: AMGN) Amgen's forecast annual revenue growth rate of 2.88% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.59%.
Amgen's revenue in 2026 is $35,971,000,000.On average, 34 Wall Street analysts forecast AMGN's revenue for 2026 to be $20,315,798,755,488, with the lowest AMGN revenue forecast at $18,858,670,059,762, and the highest AMGN revenue forecast at $21,637,230,322,122. On average, 28 Wall Street analysts forecast AMGN's revenue for 2027 to be $20,886,588,266,748, with the lowest AMGN revenue forecast at $19,333,610,011,584, and the highest AMGN revenue forecast at $23,540,759,494,107.
In 2028, AMGN is forecast to generate $20,978,129,980,818 in revenue, with the lowest revenue forecast at $16,398,351,873,963 and the highest revenue forecast at $23,546,682,781,488.